Dr Reddy’s Laboratories (DRL) has launched Levalbuterol inhalation solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials, a therapeutic equivalent generic version of Xopenex (levalbuterol hydrochloride) inhalation solution in the US market. It has been approved by the United States Food & Drug Administration (US FDA).
The Xopenex (levalbuterol hydrochloride) inhalation solution brand and generic combined had US sales of approximately $269.7 million MAT for the most recent twelve months ending in June 2014 according to IMS Health.
DRL’s Levalbuterol inhalation solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg /3 mL are available in Unit-Dose Vials of (5 x 3 mL) carton of 25. Levalbuterol inhalation solution, USP is only for use with a nebuliser.
EP News Bureau– Mumbai
